Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Section 4 of 6

Clinical evidence

370 evidence topics · 66 sources

Study summaries

COMP005

Objective
Location and study date
Study dates in the registry record
MilestoneRegistry entry
Study start (actual)“2023-01-24”
Primary completion (actual)“2025-05-28”
Study completion (actual)“2026-04-15”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics
CharacteristicCOMP360 25 mg (N=171)Placebo (N=87)
Female, n (%)“93 (54.4)”“47 (54.0)”
White, n (%)“149 (87.1)”“78 (89.7)”
Asian, n (%)“11 (6.4)”“4 (4.6)”
Black or African American, n (%)“6 (3.5)”“2 (2.3)”
American Indian or Alaska Native, n (%)“0”“1 (1.1)”
Other race, n (%)“5 (2.9)”“2 (2.3)”
Age, years, mean (SD)“45.9 (13.4)”“45.3 (14.4)”
Age, years, minimum and maximum“19, 77”“22, 72”
Age ≥65 years, n (%)“15 (8.8)”“11 (12.6)”
Prior psilocybin experience, n (%)“5 (2.9)”“5 (5.7)”
Prior psychedelic experience including psilocybin, n (%)“8 (4.7)”“6 (6.9)”
BMI, kg/m2, mean (SD)“28.4 (6.2)”“27.7 (6.1)”
Treatment history and baseline MADRS
CharacteristicCOMP360 25 mg (N=171)Placebo (N=87)
Failed treatments in current episode: 1, n (%)“2 (1.2)”“1 (1.1)”
Failed treatments in current episode: 2, n (%)“114 (66.7)”“62 (71.3)”
Failed treatments in current episode: 3, n (%)“45 (26.3)”“19 (21.8)”
Failed treatments in current episode: 4, n (%)“10 (5.8)”“4 (4.6)”
Failed treatments in current episode: 5, n (%)“0”“1 (1.1)”
Treatments withdrawn in screening: 0, n (%)“58 (33.9)”“26 (29.9)”
Treatments withdrawn in screening: 1, n (%)“38 (22.2)”“32 (36.8)”
Treatments withdrawn in screening: 2, n (%)“50 (29.2)”“21 (24.1)”
Treatments withdrawn in screening: more than 2, n (%)“25 (14.6)”“8 (9.2)”
MADRS total score at baseline, mean (SD)“31.5 (5.5)”“31.5 (5.9)”
Mild (11-19), n (%)“1 (0.6)”“2 (2.3)”
Moderate (20-30), n (%)“73 (42.7)”“33 (37.9)”
Severe (≥31), n (%)“97 (56.7)”“52 (59.8)”
Depression diagnosis history
CharacteristicCOMP360 25 mg (N=171)Placebo (N=87)
Length of current episode, months, mean (SD)“34.1 (29.1)”“38.6 (33.0)”
Current episode less than 1 year, n (%)“30 (17.5)”“20 (23.0)”
Current episode 1-2 years, n (%)“52 (30.4)”“19 (21.8)”
Current episode more than 2 years, n (%)“89 (52.0)”“48 (55.2)”
Lifetime depressive episodes, mean (SD)“7.7 (10.9)”“7.2 (7.6)”
Lifetime episodes 2-5, n (%)“107 (62.6)”“54 (62.1)”
Lifetime episodes 6-10, n (%)“40 (23.4)”“21 (24.1)”
Lifetime episodes more than 10, n (%)“23 (13.5)”“12 (13.8)”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events in Part A, through Week 6
EventCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TEAE up to Week 6“120 (70.2)”“34 (39.1)”
Any serious TEAE up to Week 6“4 (2.3)”“1 (1.1)”
Any TEAE with onset on day of dosing“118 (69.0)”“23 (26.4)”
Resolved within 1 day“111 (64.9)”“22 (25.3)”
Resolved after more than 1 and up to 2 days“15 (8.8)”“2 (2.3)”
Resolved after more than 2 days“22 (12.9)”“5 (5.7)”
Treatment-emergent adverse events in Part A with incidence above 5%
MedDRA preferred termCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TEAE“86 (50.3)”“12 (13.8)”
Headache“42 (24.6)”“10 (11.5)”
Nausea“35 (20.5)”“3 (3.4)”
Hallucination, visual“24 (14.0)”“0”
Anxiety“14 (8.2)”“2 (2.3)”
Dizziness“10 (5.8)”“2 (2.3)”
Illusion“9 (5.3)”“1 (1.1)”
Treatment-emergent serious adverse events in Part A
MedDRA preferred termCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any SAE“4 (2.3)”“1 (1.1)”
Suicidal ideation“2 (1.2)”“0”
Depression suicidal“1 (0.6)”“0”
Major depression“0”“1 (1.1)”
Cellulitis“1 (0.6)”“0”
Diverticulitis“1 (0.6)”“0”
Treatment-emergent adverse events through Week 26
EventCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TEAE up to Week 26“145 (84.8)”“52 (59.8)”
Any serious TEAE up to Week 26“8 (4.7)”“2 (2.3)”
Any TEAE with onset on day of dosing“121 (70.8”“25 (28.7)”
Resolved within 1 day“115 (67.3)”“24 (27.6)”
Resolved after more than 1 and up to 2 days“16 (9.4)”“2 (2.3)”
Resolved after more than 2 days“22 (12.9)”“5 (5.7)”
MedDRA preferred term (incidence above 10% in the 25 mg arm)COMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TEAE“145 (84.8)”“52 (59.8)”
Headache“61 (35.7)”“16 (18.4)”
Nausea“44 (25.7)”“5 (5.7)”
Hallucination, visual“27 (15.8)”“0”
Anxiety“22 (12.9)”“3 (3.4)”
Treatment-emergent serious adverse events through Week 26
MedDRA preferred termCOMP360 25 mg (N=171), n (%)Placebo (N=87), n (%)
Any TESAE“8 (4.7)”“2 (2.3)”
Suicidal ideation“4 (2.3)”“0”
Depression suicidal“1 (0.6)”“0”
Major depression“0”“1 (1.1)”
Cellulitis“1 (0.6)”“0”
Diverticulitis“1 (0.6)”“0”
Urinary tract infection bacterial“0”“1 (1.1)”
Clavicle fracture“1 (0.6)”“0”
Rib fracture“1 (0.6)”“0”
Pneumothorax“1 (0.6)”“0”
Anaphylactic reaction“1 (0.6)”“0”
Study limitations
Summary: functional unblinding, placebo comparator, observed-case and open-label follow-up, preliminary data

COMP005 compared COMP360 25 mg with a matched placebo, and the company states that concerns about functional unblinding and expectancy bias could hinder the interpretability or regulatory acceptability of its trial data. A systematic review reports that psychedelic trials have generally not reported pre-trial expectancy or blinding success and argues that their effect sizes are likely over-estimated. No statistical analyses were performed after the Week 6 primary analysis: Part B and Part C results are observed data, the responder analysis is post hoc, and protocol-allowed antidepressants were permitted in Parts B and C. Part C was open-label and was entered by approximately 70% of participants. The results are preliminary, had not been reviewed by the FDA at the 2025 topline announcement, and are reported in company documents and congress abstracts.

Blinding and expectancy confounds in psychedelic trials

COMP006

Objective
Location and study date
Study design
Eligibility criteria
Key inclusion criteria
Treatment
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics
CharacteristicCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Female, n (%)“160 (54.1)”“68 (47.9)”“69 (48.3)”
White, n (%)“255 (86.1)”“123 (86.6)”“129 (90.2)”
Asian, n (%)“14 (4.7)”“6 (4.2)”“6 (4.2)”
Black or African American, n (%)“8 (2.7)”“3 (2.1)”“4 (2.8)”
American Indian or Alaska Native, n (%)“0”“0”“1 (0.7)”
Other/not reported, n (%)“19 (6.4)”“10 (7.0)”“3 (2.1)”
Age, years, mean (SD)“46.2 (13.7)”“42.9 (12.8)”“45.5 (13.1)”
Age, min, max“18, 79”“19, 73”“20, 75”
Age ≥65 years, n (%)“29 (9.8)”“9 (6.3)”“13 (9.1)”
Prior psilocybin experience, n (%)“12 (4.1)”“5 (3.5)”“5 (3.5)”
Prior psychedelic experience including psilocybin, n (%)“20 (6.8)”“8 (5.6)”“9 (6.3)”
BMI, kg/m2, mean (SD)“28.0 (6.2)”“28.4 (6.4)”“28.0 (6.5)”
Treatment history and baseline MADRS
CharacteristicCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Failed treatments in current episode: 1, n (%)“1 (0.3)”“1 (0.7)”“0”
Failed treatments in current episode: 2, n (%)“190 (64.2)”“105 (73.9)”“98 (68.5)”
Failed treatments in current episode: 3, n (%)“74 (25.0)”“32 (22.5)”“34 (23.8)”
Failed treatments in current episode: 4, n (%)“29 (9.8)”“4 (2.8)”“11 (7.7)”
Failed treatments in current episode: 5, n (%)“2 (0.7)”“0”“0”
Treatments withdrawn in screening: 0, n (%)“68 (23.0)”“30 (21.1)”“36 (25.2)”
Treatments withdrawn in screening: 1, n (%)“127 (42.9)”“62 (43.7)”“62 (43.4)”
Treatments withdrawn in screening: 2, n (%)“68 (23.0)”“34 (23.9)”“31 (21.7)”
Treatments withdrawn in screening: more than 2, n (%)“33 (11.1)”“16 (11.3)”“14 (9.8)”
MADRS total score at baseline, mean (SD)“32.0 (5.8)”“32.1 (5.8)”“32.5 (5.4)”
Baseline MADRS subthreshold (≤10), n (%)“2 (0.7)”“0”“0”
Baseline MADRS mild (11-19), n (%)“0”“0”“0”
Baseline MADRS moderate (20-30), n (%)“115 (38.9)”“54 (38.0)”“49 (34.3)”
Baseline MADRS severe (≥31), n (%)“179 (60.5)”“88 (62.0)”“94 (65.7)”
Depression diagnosis history
CharacteristicCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Length of current episode, months, mean (SD)“45.5 (42.7)”“37.7 (38.8)”“38.4 (45.0)”
Length of current episode less than 1 year, n (%)“53 (17.9)”“37 (26.1)”“30 (21.0)”
Length of current episode 1-2 years, n (%)“73 (24.7)”“35 (24.6)”“41 (28.7)”
Length of current episode more than 2 years, n (%)“170 (57.4)”“70 (49.3)”“72 (50.3)”
Lifetime depressive episodes, mean (SD)“6.3 (7.4)”“5.4 (6.6)”“7.0 (12.5)”
Lifetime depressive episodes: 1, n (%)“1 (0.3)”“0”“0”
Lifetime depressive episodes: 2-5, n (%)“199 (67.2)”“109 (76.8)”“99 (69.2)”
Lifetime depressive episodes: 6-10, n (%)“61 (20.6)”“21 (14.8)”“30 (21.0)”
Lifetime depressive episodes: more than 10, n (%)“29 (9.8)”“10 (7.0)”“10 (7.0)”
Baseline values that differ in the February 2026 presentation
CharacteristicCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Prior psilocybin experience, n (%)“13 (4.4)”“5 (3.5)”“5 (3.5)”
Prior psychedelic experience including psilocybin, n (%)“19 (6.4)”“7 (4.9)”“9 (6.3)”
BMI, kg/m2, mean (SD)“28.0 (6.2)”“28.6 (7.1)”“27.8 (6.7)”
Failed treatments in current episode: 2, n (%)“190 (64.2)”“105 (73.9)”“99 (69.2)”
Failed treatments in current episode: 3, n (%)“74 (25.0)”“32 (22.5)”“33 (23.1)”
Treatments withdrawn in screening: 0, n (%)“68 (23.0)”“31 (21.8)”“36 (25.2)”
Treatments withdrawn in screening: 1, n (%)“127 (42.9)”“61 (43.0)”“62 (43.4)”
Treatments withdrawn in screening: 2, n (%)“68 (23.0)”“35 (24.6)”“31 (21.7)”
Treatments withdrawn in screening: more than 2, n (%)“33 (11.1)”“15 (10.6)”“14 (9.8)”
Lifetime depressive episodes: 2-5, n (%)“198 (66.9)”“109 (76.8)”“99 (69.2)”
Efficacy results
Part A key secondary endpoint: MADRS change at Week 9
Visit25 mg vs 1 mg, LS mean difference (95% CI)25 mg vs 1 mg, P-value10 mg vs 1 mg, LS mean difference (95% CI)10 mg vs 1 mg, P-value
Week 6 (primary)“-3.8 (-5.8, -1.8)”“<0.001”“-2.5 (-4.9, -0.2)”“0.016”
Week 9 (secondary)“-2.9 (-5.0, -0.9)”“0.002”“-2.6 (-5.0, -0.2)”“0.016”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Part A treatment-emergent adverse events through Week 9
MeasureCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any TEAE up to Week 9, n (%)“274 (92.6)”“125 (88.0)”“116 (81.1)”
Any serious TEAE up to Week 9, n (%)“6 (2.0)”“1 (0.7)”“5 (3.5)”
Any TEAE with onset on day of dosing, n (%)“260 (87.8)”“114 (80.3)”“80 (55.9)”
Resolved ≤1 day, n (%)“244 (82.4)”“107 (75.4)”“71 (49.7)”
Resolved >1 and ≤2 days, n (%)“52 (17.6)”“16 (11.3)”“9 (6.3)”
Resolved >2 days, n (%)“71 (24.0)”“26 (18.3)”“20 (14.0)”
Part A TEAEs with incidence above 10%
MedDRA preferred termCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any TEAE, n (%)“254 (85.8)”“111 (78.2)”“80 (55.9)”
Nausea, n (%)“118 (39.9)”“42 (29.6)”“15 (10.5)”
Headache, n (%)“108 (36.5)”“43 (30.3)”“41 (28.7)”
Anxiety, n (%)“62 (20.9)”“28 (19.7)”“21 (14.7)”
Hallucination, visual, n (%)“46 (15.5)”“24 (16.9)”“3 (2.1)”
Illusion, n (%)“41 (13.9)”“16 (11.3)”“3 (2.1)”
Dizziness, n (%)“41 (13.9)”“21 (14.8)”“9 (6.3)”
Fatigue, n (%)“41 (13.9)”“23 (16.2)”“16 (11.2)”
Crying, n (%)“35 (11.8)”“13 (9.2)”“4 (2.8)”
Blood pressure increased, n (%)“31 (10.5)”“6 (4.2)”“4 (2.8)”
Part A treatment-emergent serious adverse events
MedDRA preferred termCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any SAE, n (%)“6 (2.0)”“1 (0.7)”“5 (3.5)”
Suicidal ideation, n (%)“0”“1 (0.7)”“2 (1.4)”
Suicidal behaviour, n (%)“0”“0”“1 (0.7)”
Syncope, n (%)“1 (0.3)”“0”“1 (0.7)”
Major depression, n (%)“1 (0.3)”“0”“0”
Anxiety, n (%)“1 (0.3)”“0”“0”
Flashback, n (%)“1 (0.3)”“0”“0”
Cervical spinal stenosis, n (%)“1 (0.3)”“0”“0”
Renal neoplasm, n (%)“0”“0”“1 (0.7)”
Pelvic pain, n (%)“1 (0.3)”“0”“0”
Treatment-emergent adverse events through Week 26
MeasureCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any TEAE up to Week 26, n (%)“280 (94.6)”“132 (93.0)”“124 (86.7)”
Any serious TEAE up to Week 26, n (%)“17 (5.7)”“5 (3.5)”“9 (6.3)”
Any TEAE with onset on day of dosing, n (%)“265 (89.5)”“119 (83.8)”“88 (61.5)”
Resolved ≤1 day, n (%)“255 (86.1)”“113 (79.6)”“78 (54.5)”
Resolved >1 and ≤2 days, n (%)“60 (20.3)”“22 (15.5)”“12 (8.4)”
Resolved >2 days, n (%)“80 (27.0)”“32 (22.5)”“21 (14.7)”
Nausea, n (%)“133 (44.9)”“50 (35.2)”“18 (12.6)”
Headache, n (%)“118 (39.9)”“53 (37.3)”“49 (34.3)”
Anxiety, n (%)“83 (28.0)”“38 (26.8)”“29 (20.3)”
Hallucination, visual, n (%)“51 (17.2)”“27 (19.0)”“5 (3.5)”
Fatigue, n (%)“49 (16.6)”“26 (18.3)”“19 (13.3)”
Illusion or perceptual disturbance, n (%)“48 (16.2)”“19 (13.4)”“4 (2.8)”
Dizziness, n (%)“47 (15.9)”“25 (17.6)”“9 (6.3)”
Crying, n (%)“41 (13.9)”“15 (10.6)”“6 (4.2)”
Blood pressure increased, n (%)“35 (11.8)”“10 (7.0)”“4 (2.8)”
Treatment-emergent serious adverse events through Week 26
MedDRA preferred termCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any TESAE, n (%)“17 (5.7)”“5 (3.5)”“9 (6.3)”
Suicidal ideation, n (%)“4 (1.4)”“2 (1.4)”“4 (2.8)”
Suicidal behaviour, n (%)“0”“0”“1 (0.7)”
Suspected suicide, n (%)“1 (0.3)”“0”“0”
Suicide attempt, n (%)“0”“0”“1 (0.7)”
Syncope, n (%)“1 (0.3)”“0”“1 (0.7)”
Major depression, n (%)“1 (0.3)”“0”“0”
Anxiety, n (%)“1 (0.3)”“0”“0”
Flashback, n (%)“1 (0.3)”“0”“0”
Cervical spinal stenosis, n (%)“1 (0.3)”“0”“0”
Renal neoplasm, n (%)“0”“0”“1 (0.7)”
Pelvic pain, n (%)“1 (0.3)”“0”“0”
Adjustment disorder with mixed disturbance of emotion and conduct, n (%)“1 (0.3)”“0”“0”
Pneumonia, n (%)“0”“1 (0.7)”“0”
Radius fracture, n (%)“1 ( 0.3)”“1 (0.7)”“0”
Road traffic accident, n (%)“1 ( 0.3)”“0”“0”
Tibia fracture, n (%)“1 ( 0.3)”“0”“0”
Ulna fracture, n (%)“1 ( 0.3)”“0”“0”
Alanine aminotransferase increased, n (%)“1 ( 0.3)”“0”“0”
Aspartate aminotransferase increased, n (%)“1 ( 0.3)”“0”“0”
Brain neoplasm, n (%)“1 (0.3)”“0”“0”
Thyroid neoplasm, n (%)“1 (0.3)”“0”“0”
Cerebrovascular accident, n (%)“0”“0”“1 (0.7)”
Toxic encephalopathy, n (%)“0”“1 (0.7)”“0”
Tremor, n (%)“1 (0.3)”“0”“0”
Study limitations
Summary: functional unblinding, low-dose comparator, post hoc and observed-case analyses, preliminary data

COMP006 used COMP360 1 mg as the comparator to address “some of the functional unblinding risks of an inert placebo-control”. FDA guidance states that functional unblinding can lead to expectation bias and that enrolling participants with prior psychedelic exposure raises the possibility of expectation bias; the planned limit for prior psychedelic experience in COMP006 was 15%. One analysis found that outcomes with extremely low dose psilocybin were better than placebo response in psychedelic trials (mean difference 3.96), and a review reported that psilocybin, LSD, and ayahuasca studies “frequently reported blinding failure values of more than 90%” among participants and raters. The responder analysis is post hoc, Part B results after Week 9 are observed data, and protocol-allowed antidepressants were permitted in Parts B and C. The company describes the 26-week results as preliminary and states that full results may not be consistent with them; the registry shows no results posted.

COMP001

Objective
Location and study date
Study dates and identifiers
ItemRegistry record
Other study ID“COMP001”
Study start (actual)“2019-03-01”
Primary completion (actual)“2021-07-30”
Study completion (actual)“2021-09-27”
Results first posted“2023-04-24”
Enrollment by country
Country25 mg10 mg1 mgTotal
United States“32”“32”“32”“96”
Netherlands“17”“16”“17”“50”
United Kingdom“11”“10”“12”“33”
Spain“5”“6”“5”“16”
Ireland“3”“3”“5”“11”
Denmark“3”“2”“3”“8”
Czechia“3”“2”“2”“7”
Canada“2”“2”“2”“6”
Germany“2”“2”“0”“4”
Portugal“1”“0”“1”“2”
Study design
Registered design details
ItemRegistry record
Phase“Phase 2”
Allocation“Randomized”
Intervention model“Parallel Assignment”
Masking“Quadruple”
Primary purpose“Treatment”
Eligibility criteria
Registered eligibility criteria
ItemRegistry record
Inclusion“Diagnosis of TRD”
Exclusion“Other comorbidities”
Ages eligible“18 Years and older”
Healthy volunteers“No”
Exclusion criteria: protocol
CriterionQuoted protocol text
Psychiatric comorbidity“Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, or any serious psychiatric comorbidity as assessed by medical history and a structured clinical interview (version 7.0.2 MINI).”
Prior ECT or ketamine“Prior electroconvulsive therapy and/or ketamine for current episode.”
Substance use“Current (within the last year) alcohol or substance abuse as informed by DSM-5 at Screening (V1).”
Suicide risk“Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, at Screening or at Baseline, or; (2) suicidal behaviors within the past year, or; (3) clinical assessment of significant suicidal risk during subject interview.”
Psychedelic exposure“exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current depressive episode”
Pregnancy“Women who are pregnant, nursing, or planning a pregnancy.”
Cardiovascular“Cardiovascular conditions: recent stroke (< 1 year from signing of ICF), recent myocardial infarction (< 1 year from signing of ICF), hypertension (blood pressure > 140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF.”
Diabetes“Uncontrolled insulin-dependent diabetes.”
Seizures“Seizure disorder.”
Treatment
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment: registry record
Enrollment typeParticipants
Actual“233”
Participants analyzed for the primary endpoint
Analysis25 mg10 mg1 mg
Full analysis set (primary)“79”“75”“79”
Per-protocol set (sensitivity)“77”“65”“68”
Description of analysis sets
Results
Participant disposition
Participant flow: registry results
Status25 mg10 mg1 mg
Started“79”“75”“79”
Completed“74”“66”“69”
Not completed“5”“9”“10”
Baseline characteristics
Demographics: registry results
Characteristic25 mg10 mg1 mgTotal
Participants“79”“75”“79”“233”
Age, mean (SD), years“40.2(12.19)”“40.6(12.76)”“38.7(11.71)”“39.8(12.19)”
Age 65 years or older“3”“2”“2”“7”
Female“35”“34”“43”“112”
Male“44”“41”“36”“121”
White“70”“72”“73”“215”
Asian“4”“3”“5”“12”
Black or African American“4”“0”“1”“5”
Efficacy results
Observed MADRS change at Week 3: registry results
Analysis set25 mg10 mg1 mg
Full analysis set, mean (SD)“-12(12.98)”“-8.9(10.94)”“-6.8(11.10)”
Per-protocol set, mean (SD)“-12(12.98)”“-8.9(11.11)”“-6.7(11.18)”
Health-related quality of life and patient-reported outcomes
Safety results
Serious adverse events through Week 12: registry results
Study limitations
Summary: functional unblinding, low-dose comparator without an active treatment, antidepressant washout, Week 3 primary endpoint

The authors state that interpretation is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose, and that larger and longer trials, including comparison with existing treatments, are required. Published correspondence disputed the description of the trial as double-blind. The primary endpoint was at Week 3, and the authors state that in the 25 mg group, sustained response at 12 weeks was not generally supportive of the primary results. Participants tapered antidepressants at least two weeks before baseline and were asked to remain off them for at least 3 weeks after dosing; a commentary notes that many started other antidepressants after Week 3. The same commentary notes emergent suicidal ideation and behavior in the 25 mg and 10 mg groups and not in the 1 mg group, and the publication reports suicidal ideation or behavior or self-injury in all dose groups.

COMP004

Objective
Location and study date
Study dates and identifiers
ItemRegistry record
Other study ID“COMP004”
Study start (actual)“2020-07-20”
Primary completion (actual)“2022-08-11”
Study completion (actual)“2022-08-11”
Last update posted“2022-09-22”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using time to depressive event as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment: registry record
Enrollment typeParticipants
Actual“66”
Planned enrollment

No evidence found.

Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary: observational design, selected subgroup, few events, post hoc analysis

COMP004 was an observational follow-up that enrolled 66 participants who had completed COMP001 or COMP003, 58 of them from COMP001. The prespecified primary analysis covered all COMP001 participants, and the analysis restricted to enrolled participants was post hoc and based on 10 depressive events after enrollment. At entry, more participants in the 1 mg group were taking antidepressant medication (10, compared with 9 in the 10 mg and 6 in the 25 mg group). The published and Form 10-K medians for the 10 mg group differ (83 and 86 days). The authors state that larger long-term studies are required, and FDA guidance describes blinded long-term follow-up with prespecified retreatment criteria as the most informative design.

COMP003

Objective
Location and study date
Registry dates and locations
FieldRegistry entry
Study start (actual)“2020-08-10”
Primary completion (actual)“2021-10-14”
Study completion (actual)“2021-10-14”
United States site“Kadima Neuropsychiatry Institute”
Ireland site“Sheaf House, Tallaght Hospital”
Study design
Eligibility criteria
Treatment
Single 25 mg dose during a monitored session
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registry enrollment
FieldRegistry entry
Enrollment (actual)“19”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographic and clinical characteristics, safety analysis set
CharacteristicCOMP360 25 mg + SSRI (N = 19)
Female, n (%)“13 (68.4)”View highlighted excerpt for this quote
Age, years, mean (SD)“42.2 (10.80)”View highlighted excerpt for this quote
Race, White, n (%)“15 (78.9)”View highlighted excerpt for this quote
Body mass index, kg/m2, mean (SD)“26.26 (6.521)”View highlighted excerpt for this quote
Duration of current episode 1 year to <2 years, n (%)“13 (68.4)”View highlighted excerpt for this quote
Duration of current episode >2 years, n (%)“3 (15.8)”View highlighted excerpt for this quote
Failed treatments in current episode: 2, n (%)“12 (63.2)”View highlighted excerpt for this quote
Failed treatments in current episode: 3 or 4, n (%)“7 (36.8)”View highlighted excerpt for this quote
Ongoing sertraline, n (%) [min dose, max dose]“6 (31.6) [50 mg, 200 mg]”View highlighted excerpt for this quote
Ongoing escitalopram, n (%) [min dose, max dose]“6 (31.6) [5 mg, 20 mg]”View highlighted excerpt for this quote
Ongoing fluoxetine, n (%) [min dose, max dose]“3 (15.8%) [20 mg, 80 mg]”View highlighted excerpt for this quote
Ongoing vilazodone, n (%) [min dose, max dose]“2 (10.5%) [20 mg, 40 mg]”View highlighted excerpt for this quote
Ongoing paroxetine, n (%) [dose]“1 (5.3%) [60 mg]”View highlighted excerpt for this quote
Ongoing citalopram, n (%) [dose]“1 (5.3%) [20 mg]”View highlighted excerpt for this quote
Duration of SSRI treatment prior to Baseline, months, mean (SD)“14.68 (13.213)”View highlighted excerpt for this quote
MADRS total score, mean (SD)“31.7 (5.77)”View highlighted excerpt for this quote
MADRS moderate (20 to 30), n (%)“7 (36.8)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events from Day 1 to Week 3, safety analysis set
Period and eventParticipants, n (%)Events
Overall: any TEAE“12 (63.2)”View highlighted excerpt for this quote“17”View highlighted excerpt for this quote
Overall: any severe TEAE“2 (10.5)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Overall: any serious TEAE“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Day 1: any TEAE“9 (47.4)”View highlighted excerpt for this quote“11”View highlighted excerpt for this quote
Day 1: headache“4 (21.1)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote
Day 1: blood pressure increased“3 (15.8)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Day 1: dizziness“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Day 1: dry mouth“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Day 1: fall“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Day 1: skin abrasion“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
After Day 1 to Week 3: any TEAE“4 (21.1)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote
After Day 1 to Week 3: headache“2 (10.5)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
After Day 1 to Week 3: depression“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
After Day 1 to Week 3: diarrhea“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
After Day 1 to Week 3: palpitations“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
After Day 1 to Week 3: vertigo“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Study limitations
Summary: open-label single-arm design, small sample, short follow-up, blood pressure measurement, sponsor analysis

The authors state that the study was limited by its small size, open-label design and absence of a comparator, a sample that was not demographically diverse, and the exclusion of participants with high suicide risk or current hospitalization, and that the open-label design may have influenced participant expectations. Nineteen participants were dosed, no formal sample size calculation was performed, efficacy was summarized descriptively, and follow-up lasted three weeks. Blood pressure elevations were recorded with a finger cuff system that was not accurately calibrated. The sponsor performed the data review, interpretation, and post hoc analyses, and several authors are current or past employees of COMPASS Pathfinder. The authors state that the findings need confirmation in a larger, double-blind, comparator-controlled study.

PsiDeR

Objective
Location and study date
Registry dates and location
FieldRegistry entry
Study start (actual)“2021-06-21”
Primary completion (actual)“2024-12-18”
Study completion (actual)“2024-12-18”
Location“Clinical Research Facility, King's College Hospital”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using recruitment and retention rates as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Minimization factors and baseline demographics by arm
CharacteristicPlacebo (N = 30)Psilocybin (N = 30)Overall (N = 60)
Female, n (%)“15 (50%)”View highlighted excerpt for this quote“15 (50%)”View highlighted excerpt for this quote“30 (50%)”View highlighted excerpt for this quote
Age group 60 or older, n (%)“3 (10%)”View highlighted excerpt for this quote“3 (10%)”View highlighted excerpt for this quote“6 (10%)”View highlighted excerpt for this quote
Past psilocybin use, n (%)“5 (17%)”View highlighted excerpt for this quote“4 (13%)”View highlighted excerpt for this quote“9 (15%)”View highlighted excerpt for this quote
Age at randomization, median (IQR)“40.2 (33.7−52.0)”View highlighted excerpt for this quote“41.7 (38.6−57.0)”View highlighted excerpt for this quote“40.8 (35.2−52.3)”View highlighted excerpt for this quote
HAM-D-17 score, median (IQR)“17.0 (15.0−21.0)”View highlighted excerpt for this quote“18.5 (16.0−21.0)”View highlighted excerpt for this quote“18.0 (15.0−21.0)”View highlighted excerpt for this quote
Ethnicity White, n (%)“24 (80%)”View highlighted excerpt for this quote“21 (70%)”View highlighted excerpt for this quote“45 (75%)”View highlighted excerpt for this quote
Postgraduate degree, n (%)“14 (47%)”View highlighted excerpt for this quote“11 (37%)”View highlighted excerpt for this quote“25 (42%)”View highlighted excerpt for this quote
Full-time employed, n (%)“11 (37%)”View highlighted excerpt for this quote“15 (50%)”View highlighted excerpt for this quote“26 (43%)”View highlighted excerpt for this quote
First-degree family history of depression, n (%)“15 (50%)”View highlighted excerpt for this quote“18 (60%)”View highlighted excerpt for this quote“33 (55%)”View highlighted excerpt for this quote
Years spent with feelings of significant depression, mean (s.d.)“19.2 (10.3)”View highlighted excerpt for this quote“20.9 (10.2)”View highlighted excerpt for this quote“20.0 (10.2)”View highlighted excerpt for this quote
Maudsley Staging Method score at screening, median (IQR)“8.0 (7.0−9.0)”View highlighted excerpt for this quote“8.0 (7.0−10.0)”View highlighted excerpt for this quote“8.0 (7.0−9.5)”View highlighted excerpt for this quote
Efficacy results
Primary feasibility outcomes
Health-related quality of life and patient-reported outcomes
Adjusted mean differences in patient-reported outcomes
Scale and timepointMean difference (95% CI)Cohen's d (95% CI)
QIDS-SR-16, Week 3“−5.48 (−7.85 to −3.12)”View highlighted excerpt for this quote“−1.19 (−1.7 to −0.67)”View highlighted excerpt for this quote
QIDS-SR-16, Week 6“−5.63 (−8.00 to −3.27)”View highlighted excerpt for this quote“−1.22 (−1.73 to −0.71)”View highlighted excerpt for this quote
GAD-7, Week 3“−4.85 (−6.96 to −2.74)”View highlighted excerpt for this quote“−1.00 (−1.44 to −0.57)”View highlighted excerpt for this quote
GAD-7, Week 6“−4.54 (−6.64 to −2.44)”View highlighted excerpt for this quote“−0.94 (−1.37 to −0.50)”View highlighted excerpt for this quote
EQ-5D-5L VAS, Week 3“12.46 (3.39−21.54)”View highlighted excerpt for this quote“0.62 (0.17−1.07)”View highlighted excerpt for this quote
EQ-5D-5L VAS, Week 6“10.69 (1.63−19.75)”View highlighted excerpt for this quote“0.53 (0.08−0.98)”View highlighted excerpt for this quote
WSAS, Week 3“−8.20 (−12.09 to −4.30)”View highlighted excerpt for this quote“−1.26 (−1.86 to −0.66)”View highlighted excerpt for this quote
WSAS, Week 6“−9.22 (−13.08 to −5.36)”View highlighted excerpt for this quote“−1.42 (−2.02 to −0.83)”View highlighted excerpt for this quote
M3VAS, Week 3“45.33 (19.69−70.96)”View highlighted excerpt for this quote“1.17 (0.51−1.83)”View highlighted excerpt for this quote
M3VAS, Week 6“36.42 (10.80−62.04)”View highlighted excerpt for this quote“0.94 (0.28−1.60)”View highlighted excerpt for this quote
WEMWBS, Week 3“10.48 (6.57−14.40)”View highlighted excerpt for this quote“1.76 (1.10−2.42)”View highlighted excerpt for this quote
WEMWBS, Week 6“9.44 (5.55−13.32)”View highlighted excerpt for this quote“1.59 (0.93−2.24)”View highlighted excerpt for this quote
Safety results
Nonserious adverse events during the randomized phase (randomization to Week 6)
CategoryPlacebo (123 events; 28 reporters)Psilocybin (164 events; 30 reporters)Overall (287 events; 58 reporters)
Neurological, events (reporters)“32 (17)”View highlighted excerpt for this quote“53 (26)”View highlighted excerpt for this quote“85 (43)”View highlighted excerpt for this quote
Mood/psychological, events (reporters)“13 (9)”View highlighted excerpt for this quote“30 (18)”View highlighted excerpt for this quote“43 (27)”View highlighted excerpt for this quote
Respiratory infection, events (reporters)“24 (16)”View highlighted excerpt for this quote“12 (11)”View highlighted excerpt for this quote“36 (27)”View highlighted excerpt for this quote
Gastrointestinal, events (reporters)“8 (6)”View highlighted excerpt for this quote“15 (12)”View highlighted excerpt for this quote“23 (18)”View highlighted excerpt for this quote
Musculoskeletal/pain, events (reporters)“13 (11)”View highlighted excerpt for this quote“14 (9)”View highlighted excerpt for this quote“27 (20)”View highlighted excerpt for this quote
Medication or substance related, events (reporters)“5 (5)”View highlighted excerpt for this quote“10 (9)”View highlighted excerpt for this quote“15 (14)”View highlighted excerpt for this quote
General fatigue/tiredness, events (reporters)“4 (4)”View highlighted excerpt for this quote“8 (8)”View highlighted excerpt for this quote“12 (12)”View highlighted excerpt for this quote
Related to study medication, n (%)“2 (2%)”View highlighted excerpt for this quote“29 (18%)”View highlighted excerpt for this quote“31 (11%)”View highlighted excerpt for this quote
Possibly related, n (%)“16 (13%)”View highlighted excerpt for this quote“56 (34%)”View highlighted excerpt for this quote“72 (25%)”View highlighted excerpt for this quote
Mild intensity, n (%)“77 (63%)”View highlighted excerpt for this quote“111 (68%)”View highlighted excerpt for this quote“188 (66%)”View highlighted excerpt for this quote
Moderate intensity, n (%)“45 (37%)”View highlighted excerpt for this quote“48 (29%)”View highlighted excerpt for this quote“93 (32%)”View highlighted excerpt for this quote
Severe intensity, n (%)“1 (1%)”View highlighted excerpt for this quote“5 (3%)”View highlighted excerpt for this quote“6 (2%)”View highlighted excerpt for this quote
Adverse events of special interest, n (%)“0 (0%)”View highlighted excerpt for this quote“0 (0%)”View highlighted excerpt for this quote“0 (0%)”View highlighted excerpt for this quote
Study limitations
Summary: functional unblinding, inactive placebo with little placebo response, feasibility design, single site, sample composition

PsiDeR was a single-site feasibility trial of 60 participants with 6 weeks of follow-up and no hypothesis testing. Blinding was assessed in a subsample of 23 participants after a measure was introduced part-way through the trial: 13 of 13 (100%) in the psilocybin arm and 7 of 10 (70%) in the placebo arm correctly guessed their allocation, and the authors state that “expectancy effects in both groups likely account for some of the between-group difference observed”. The placebo arm did not show meaningful reductions in MADRS or QIDS-SR scores, and the authors note that active placebos or subperceptual doses may be more appropriate for efficacy trials. The sample was highly educated, recruitment targets were not met for Black, African, Caribbean or Black British participants, and about half of participants used facilities opened under a later financial agreement with COMPASS Pathways.

EudraCT 2018-000978-30

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Group preparation, simultaneous administration session, and integration

“During this visit, participants attended a 2-h group preparatory session (involving all participants to be dosed the following day, a lead therapist and assisting therapists) and had a short (5–15 min) individual discussion with their assigned assisting therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Administration sessions generally lasted ~6–8 h, with psychological support available throughout from specially trained assisting therapists, who were supervised by a lead therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The simultaneous dosing involved each participant having a private space, for example, a bed separated by curtains within the same room, so they could focus on their own experience with minimal distractions, especially as participants were encouraged to wear eyeshades, earplugs and/or earphones for the duration of the administration session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants were subsequently discharged and asked to return the following day (day 1; visit 4) for safety assessments and a discussion with their allocated therapist about the subjective experience during the administration session (integration session).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Study outcomes
Rationale for using CANTAB cognitive measures as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Participant demographics, safety population
CharacteristicPsilocybin 25 mg (N = 30)Psilocybin 10 mg (N = 30)Placebo (N = 29)Overall (N = 89)
Male, n (%)“16 (53.3)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“16 (55.2)”View highlighted excerpt for this quote“48 (53.9)”View highlighted excerpt for this quote
Female, n (%)“14 (46.7)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“13 (44.8)”View highlighted excerpt for this quote“41 (46.1)”View highlighted excerpt for this quote
White, n (%)“25 (83.3)”View highlighted excerpt for this quote“27 (90.0)”View highlighted excerpt for this quote“20 (69.0)”View highlighted excerpt for this quote“72 (80.9)”View highlighted excerpt for this quote
Age at consent, years, mean (SD)“36.6 (10.29)”View highlighted excerpt for this quote“36.1 (9.25)”View highlighted excerpt for this quote“35.6 (7.69)”View highlighted excerpt for this quote“36.1 (9.06)”View highlighted excerpt for this quote
BMI, kg/m2, mean (SD)“22.9 (3.75)”View highlighted excerpt for this quote“23.0 (2.90)”View highlighted excerpt for this quote“23.7 (3.20)”View highlighted excerpt for this quote“23.2 (3.29)”View highlighted excerpt for this quote
Undergraduate or higher national diploma, n (%)“9 (30.0)”View highlighted excerpt for this quote“11 (36.7)”View highlighted excerpt for this quote“10 (34.5)”View highlighted excerpt for this quote“30 (33.7)”View highlighted excerpt for this quote
Master’s or postgraduate diploma, n (%)“16 (53.3)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“15 (51.7)”View highlighted excerpt for this quote“47 (52.8)”View highlighted excerpt for this quote
PhD, n (%)“3 (10.0)”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“4 (13.8)”View highlighted excerpt for this quote“9 (10.1)”View highlighted excerpt for this quote
Prior psilocybin experience, n (%)“11 (36.7)”View highlighted excerpt for this quote“15 (50.0)”View highlighted excerpt for this quote“7 (24.1)”View highlighted excerpt for this quote“33 (37.1)”View highlighted excerpt for this quote
Efficacy results
CANTAB measures: least squares mean difference from placebo
CANTAB measure and doseDay 8, LS mean (95% CI) difference from placeboDay 29, LS mean (95% CI) difference from placebo
Global composite, 10 mg“−0.1960 (−0.39172, −0.00024)”View highlighted excerpt for this quote“0.0364 (−0.21234, 0.28505)”View highlighted excerpt for this quote
Global composite, 25 mg“−0.1167 (−0.31228, 0.07898)”View highlighted excerpt for this quote“0.1519 (−0.09846, 0.40219)”View highlighted excerpt for this quote
PAL-TEA, 10 mg“2.5 (−0.57, 5.65)”View highlighted excerpt for this quote“−2.4 (−6.48, 1.59)”View highlighted excerpt for this quote
PAL-TEA, 25 mg“−0.5 (−3.60, 2.60)”View highlighted excerpt for this quote“−2.5 (−6.59, 1.52)”View highlighted excerpt for this quote
SWM-BE, 10 mg“1.5 (−1.27, 4.27)”View highlighted excerpt for this quote“1.7 (−0.56, 4.02)”View highlighted excerpt for this quote
SWM-BE, 25 mg“1.7 (−1.02, 4.51)”View highlighted excerpt for this quote“0.5 (−1.83, 2.77)”View highlighted excerpt for this quote
SWM-S, 10 mg“0.4 (−0.46, 1.26)”View highlighted excerpt for this quote“0.2 (−0.78, 1.16)”View highlighted excerpt for this quote
SWM-S, 25 mg“0.3 (−0.59, 1.12)”View highlighted excerpt for this quote“−0.4 (−1.35, 0.60)”View highlighted excerpt for this quote
RVP-A’, 10 mg“−0.0017 (−0.00984, 0.00651)”View highlighted excerpt for this quote“0.0103 (−0.00464, 0.02524)”View highlighted excerpt for this quote
RVP-A’, 25 mg“−0.0053 (−0.01348, 0.00286)”View highlighted excerpt for this quote“0.0099 (−0.00519, 0.02490)”View highlighted excerpt for this quote
Social cognition and emotional processing scales: least squares mean difference from placebo
Scale and doseDay 8, LS mean (95% CI) difference from placeboDay 85, LS mean (95% CI) difference from placebo
PET, 10 mg“−0.1 (−0.39, 0.15)”View highlighted excerpt for this quote“−0.1 (−0.39, 0.15)”View highlighted excerpt for this quote
PET, 25 mg“0.2 (−0.11, 0.42)”View highlighted excerpt for this quote“0.1 (−0.12, 0.41)”View highlighted excerpt for this quote
RMET, 10 mg“0.1 (−1.43, 1.69)”View highlighted excerpt for this quote“0.2 (−1.53, 1.95)”View highlighted excerpt for this quote
RMET, 25 mg“0.2 (−1.44, 1.74)”View highlighted excerpt for this quote“0.5 (−1.29, 2.28)”View highlighted excerpt for this quote
SSR Global, 10 mg“1.2 (−2.16, 4.56)”View highlighted excerpt for this quote“0.3 (−2.83, 3.49)”View highlighted excerpt for this quote
SSR Global, 25 mg“2.8 (−0.50, 6.18)”View highlighted excerpt for this quote“2.2 (−0.94, 5.29)”View highlighted excerpt for this quote
SVO Angle, 10 mg“3.4 (−0.05, 6.85)”View highlighted excerpt for this quote“3.4 (−0.16, 6.97)”View highlighted excerpt for this quote
SVO Angle, 25 mg“2.1 (−1.32, 5.58)”View highlighted excerpt for this quote“2.4 (−1.16, 6.06)”View highlighted excerpt for this quote
TEQ, 10 mg“0.1 (−0.16, 0.31)”View highlighted excerpt for this quote“0.1 (−0.15, 0.34)”View highlighted excerpt for this quote
TEQ, 25 mg“0.2 (−0.08, 0.38)”View highlighted excerpt for this quote“0.1 (−0.13, 0.36)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Safety results
Most frequent treatment-emergent adverse events and events of special interest, safety population
TEAE (MedDRA preferred term)25 mg, n (%)25 mg, events10 mg, n (%)10 mg, eventsPlacebo, n (%)Placebo, events
Hallucination, visual“21 (70.0)”View highlighted excerpt for this quote“22”View highlighted excerpt for this quote“18 (60.0)”View highlighted excerpt for this quote“20”View highlighted excerpt for this quote“2 (6.9)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Illusion“18 (60.0)”View highlighted excerpt for this quote“26”View highlighted excerpt for this quote“19 (63.3)”View highlighted excerpt for this quote“25”View highlighted excerpt for this quote“4 (13.8)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Mood altered“15 (50.0)”View highlighted excerpt for this quote“25”View highlighted excerpt for this quote“13 (43.3)”View highlighted excerpt for this quote“23”View highlighted excerpt for this quote“6 (20.7)”View highlighted excerpt for this quote“9”View highlighted excerpt for this quote
Headache“15 (50.0)”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote“9 (30.0)”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote“5 (17.2)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Fatigue“8 (26.7)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“9 (30.0)”View highlighted excerpt for this quote“10”View highlighted excerpt for this quote“3 (10.3)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Euphoric mood“7 (23.3)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“7 (23.3)”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Tension headache“6 (20.0)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“3 (10.0)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3 (10.3)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Time perception altered“6 (20.0)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“3 (10.3)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Emotional disorder“5 (16.7)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Somatic hallucination“5 (16.7)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“8 (26.7)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“4 (13.8)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Affect lability“3 (10.0)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“5 (16.7)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote“1 (3.4)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Any TEAE of special interest“26 (86.7)”View highlighted excerpt for this quote“80”View highlighted excerpt for this quote“25 (83.3)”View highlighted excerpt for this quote“81”View highlighted excerpt for this quote“10 (34.5)”View highlighted excerpt for this quote“19”View highlighted excerpt for this quote
Substance-induced psychotic disorder“1 (3.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Study limitations
Summary: healthy participants, exploratory sample size, blinding not assessed, practice effects, sponsor involvement

The study enrolled 89 healthy participants who were typically highly educated, and 37% of the sample had previous psilocybin experience; the authors state that these factors and the small sample size could have limited generalisability and that the findings warrant investigation in clinical populations. The sample size was not powered to detect statistically significant differences, and p values were not reported. Blinding efficacy was not assessed, and the authors state that participants may have been able to determine their assigned treatment group. Practice effects could have influenced results, and outcomes were measured at day 8 and at day 29 or 85. The study was funded and sponsored by COMPASS Pathways, and several authors are employees or former employees of the company.